Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study

References

• World Health Organization: Cancer [Internet]. WHO. c2023 [cited 2022 Sep 13]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer
   Google Scholar
• Travis WD, Brambilla E, Nicholson AG, et al. The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–1260. doi:10.1097/JTO.0000000000000630.
   PubMed Web of Science ®Google Scholar
• Travis WD. Pathology of lung cancer. Clin Chest Med. 2011;32(4):669–692. doi:10.1016/j.ccm.2011.08.005.
   PubMed Web of Science ®Google Scholar
• Cersosimo RJ. Lung cancer: a review. Am J Health Syst Pharm. 2002;59(7):611–642. doi:10.1093/ajhp/59.7.611.
   PubMed Web of Science ®Google Scholar
• Goksel T, Eser S, Guclu S, et al. Prognostic factors affecting survival in cases with lung cancer [a lung cancer mapping project in Turkey (LCMPT)]. Eur Respir J. 2013;42(Suppl 57):2920.
   Google Scholar
• Gridelli C, Peters S, Mok T, et al. First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an international expert panel meeting by the Italian association of thoracic oncology. ESMO Open. 2022;7(1):100355. doi:10.1016/j.esmoop.2021.100355.
   PubMed Web of Science ®Google Scholar
• Areses Manrique MC, Mosquera Martínez J, García González J, et al. Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience. Transl Lung Cancer Res. 2018;7(3):404–415. doi:10.21037/tlcr.2018.04.03.
   PubMed Web of Science ®Google Scholar
• Ezeife DA, Leighl NB. Personalized medicine for non-small cell lung cancer: where are we now and where can we go? Expert Rev Respir Med. 2018;12(2):81–82. doi:10.1080/17476348.2018.1411805.
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974–1982. doi:10.1200/JCO.2014.59.4358.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc3239.
   PubMed Web of Science ®Google Scholar
• Raju S, Joseph R, Sehgal S. Review of checkpoint immunotherapy for the management of non-small cell lung cancer. Immunotargets Ther. 2018;7:63–75. doi:10.2147/ITT.S125070.
   PubMed Web of Science ®Google Scholar
• Kazandjian D, Suzman DL, Blumenthal G, et al. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist. 2016;21(5):634–642. doi:10.1634/theoncologist.2015-0507.
   PubMed Web of Science ®Google Scholar
• TC. Sağlık Bakanlığı Türkiye İlaç ve Tıbbi Cihaz Kurumu: Kısa Ürün Bilgisi [Internet]. Ankara: TİTCK [cited 2023 Jul 13]. Available from: https://titck.gov.tr/storage/Archive/2022/kubKtAttachments/TTCKOnaylKBOPDIVO40MG_d3b2004d-15f5-4052-a983-9c83bf3f0ce2.pdf.
   Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. Erratum in: CA Cancer J Clin. 2021;71(4):359. doi:10.3322/caac.21654.
   PubMed Web of Science ®Google Scholar
• Armoiry X, Tsertsvadze A, Connock M, et al. Comparative efficacy and safety of licensed treatments for previously treated non-small cell lung cancer: a systematic review and network meta-analysis. PLoS One. 2018;13(7):e0199575. doi:10.1371/journal.pone.0199575.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639. doi:10.1056/NEJMoa1507643.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135. doi:10.1056/NEJMoa1504627.
   PubMed Web of Science ®Google Scholar
• Vokes EE, Ready N, Felip E, et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018;29(4):959–965. doi:10.1093/annonc/mdy041.
   PubMed Web of Science ®Google Scholar
• Horinouchi H, Nishio M, Hida T, et al. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: pooled analysis of ONO-4538-05 and ONO-4538-06 studies. Cancer Med. 2019;8(11):5183–5193. doi:10.1002/cam4.2411.
   PubMed Web of Science ®Google Scholar
• Dudnik E, Moskovitz M, Daher S, et al. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: the real-life data. Lung Cancer. 2018;126:217–223. doi:10.1016/j.lungcan.2017.11.015.
   PubMed Web of Science ®Google Scholar
• Gettinger SN, Horn L, Gandhi L, et al. Long-term survival, clinical activity, and safety of nivolumab (anti-PD-1; BMS-936558, ONO-4538) in patients (pts) with advanced non-small cell lung cancer (NSCLC) metastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014;90(5):S34. doi:10.1016/j.ijrobp.2014.08.209.
   Google Scholar
• Morita R, Okishio K, Shimizu J, et al. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: a multicenter retrospective observational study in Japan. Lung Cancer. 2020;140:8–18. doi:10.1016/j.lungcan.2019.11.014.
   PubMed Web of Science ®Google Scholar
• Brustugun OT, Sprauten M, Helland Å. Real-world data on nivolumab treatment of non-small cell lung cancer. Acta Oncol. 2017;56(3):438–440. doi:10.1080/0284186X.2016.1253865.
   PubMed Web of Science ®Google Scholar
• Figueiredo A, Almeida MA, Almodovar MT, et al. Real-world data from the Portuguese nivolumab expanded access program (EAP) in previously treated non small cell lung cancer (NSCLC). Pulmonology. 2020;26(1):10–17. doi:10.1016/j.pulmoe.2019.06.001.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. What are the risk factors for lung cancer? [Internet] Atlanta (GA): CDC [cited 2022 Sep10]. Available from: https://www.cdc.gov/cancer/lung/basic_info/risk_factors.htm.
   Google Scholar
• T.C. Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu: Ulusal Kanser Kontrol Planı 2013 – 2018 [Internet]. Ankara: Halk Sağlığı Genel Müdürlüğü; c2023 [cited 2022 Sep 10]. Available from: https://www.iccp-portal.org/system/files/plans/Ulusal_Kanser_Kontrol_Plani_2013_2018.pdf
   Google Scholar
• Nishio M, Hida T, Atagi S, et al. Multicentre phase II study of nivolumab in japanese patients with advanced or recurrent non-squamous non-small cell lung cancer. ESMO Open. 2016;1(4):e000108. doi:10.1136/esmoopen-2016-000108.
   PubMedGoogle Scholar
• Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257–265. doi:10.1016/S1470-2045(15)70054-9.
   PubMed Web of Science ®Google Scholar